ResApp Health’s respiratory diagnostic test to be integrated into Australian telehealth platform

ResApp Health ASX RAP respiratory diagnostic test integrated Australian telehealth platform Coviu
ResApp Health’s ResAppDx-EU technology will be integrated into Coviu’s telehealth platform which serves more than 5,500 clinicians Australia-wide.

ResApp Health (ASX: RAP) has entered an agreement to have its acute respiratory diagnostic test integrated into Australia’s leading telehealth software platform Coviu.

According to ResApp, the integration of its diagnostic technology ResAppDx-EU into Coviu will see it made available to more than 5,500 clinicians across 1,000 clinics who currently use the platform.

Coviu is a spin out from Australia’s leading scientific research body CSIRO’s Data61 technology and now powers the Australian Government-funded healthdirect video call.

ResApp managing director and chief executive officer Tony Keating said the company was “excited” to be working with Coviu.

“This is a great opportunity to integrate ResApp’s solution into a leading telehealth provider’s platform and demonstrate the value we deliver in the telehealth setting,” Mr Keating added.

Over the next four months, Coviu and ResApp will work together to integrate ReAppDx-EU into Coviu’s platform, including developing a workflow for directing patients to ResAppDx-EU in appropriate circumstances and developing a list of actions for clinicians after reviewing the results.

The duo is expected to negotiate the cost model before the conclusion of the four month project.

ResAppDx-EU respiratory diagnostic tool

ResApp’s technology is a clinically validated and regulatory-approved respiratory smartphone-based diagnostic test.

The smartphone app uses machine learning algorithms to analyse a patient’s cough sounds.

Clinicians can then use the app to accurately diagnose lower respiratory tract disease, croup, pneumonia, asthma, reactive airway disease and bronchiolitis.

The technology has received CE Mark certification in the EU for paediatric and adult use and gained Therapeutic Goods Administration approval in Australia for paediatric use, with adult certification pending.

ResApp has also submitted a De Novo application for the technology with the US Food and Drug Administration.

The company anticipates it will receive a decision for paediatric use in the US within six months along with TGA approval for use in adults.

In early morning trade, ResApp’s shares had risen 7.41% to $0.29.